<Research>CLSA Maintains Outperform Rating for WUXI BIO (02269.HK) Due to Enhanced Growth Acceleration Prospects
WUXI BIO Performance: Since January 20, WUXI BIO's share price has shown positive performance, surpassing its Chinese CRO peers and the healthcare sector, with a current price increase of 0.565%.
Market Insights: CLSA's research indicates that WUXI BIO's diversified shareholder structure provides resilience against geopolitical risks, and there is potential for growth acceleration before 2026, possibly exceeding expectations.
Investment Recommendations: Daiwa has rated WUXI BIO as a Buy, and the company is highlighted as a top pick in China's CRO/CDMO sector, with a target price of $48.5 and an Outperform rating.
Short Selling Data: As of January 22, 2026, WUXI BIO has experienced significant short selling, amounting to $189.95 million, with a short selling ratio of 13.739%.
Get Free Real-Time Notifications for Any Stock
Analyst Views on 02269
About the author
<Research>CLSA Maintains Outperform Rating for WUXI BIO (02269.HK) Due to Enhanced Growth Acceleration Prospects
WUXI BIO Performance: Since January 20, WUXI BIO's share price has shown positive performance, surpassing its Chinese CRO peers and the healthcare sector, with a current price increase of 0.565%.
Market Insights: CLSA's research indicates that WUXI BIO's diversified shareholder structure provides resilience against geopolitical risks, and there is potential for growth acceleration before 2026, possibly exceeding expectations.
Investment Recommendations: Daiwa has rated WUXI BIO as a Buy, and the company is highlighted as a top pick in China's CRO/CDMO sector, with a target price of $48.5 and an Outperform rating.
Short Selling Data: As of January 22, 2026, WUXI BIO has experienced significant short selling, amounting to $189.95 million, with a short selling ratio of 13.739%.
Guosen Securities Reveals Top 10 HK Stocks with Highest Foreign Capital Inflows and Outflows in Q4 2025 (Table)
Top Inflows: Guosen Securities reported the top ten Hong Kong stocks with the largest foreign capital inflows in 4Q25, led by INNOVENT BIO with an inflow of HKD6.43 billion.
Top Outflows: The report also highlighted the top ten stocks with the largest foreign capital outflows, with XIAOMI-W experiencing the highest outflow of HKD50.41 billion.
Short Selling Data: The report included short selling data for each stock, indicating significant short selling activity, particularly for XIAOMI-W and HSBC HOLDINGS.
Market Trends: The report reflects ongoing trends in the Hong Kong stock market, with notable shifts in foreign investment and short selling strategies among major companies.
